Clinical Trial Update: Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) [Phase 3]

View source ↗

Summary

Phase 3 LEAP-002 trial comparing lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma completed, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Hepatocellular | Phase 3 | Status: COMPLETED | Results posted: 2023-07-24